Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib and Venetoclax in Treatment-naïve Waldenström Macroglobulinemia
NCT04273139Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax in Waldenström macroglobulinemia (WM), sponsored by Dana-Farber Cancer Institute. Started Jul 2020; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT04273139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04273139.